NASDAQ:EDGE Edge Therapeutics Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Edge Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.33 -0.03 (-1.27 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$2.28Now: $2.33▼$2.4150-Day Range$0.50MA: $4.11▼$6.7152-Week Range$0.28Now: $2.33▼$17.38Volume225,303 shsAverage Volume373,201 shsMarket Capitalization$73.42 millionP/E RatioN/ADividend YieldN/ABeta3.65 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Edge Therapeutics. Previous Next 2.5 Community Rank Outperform VotesEdge Therapeutics has received 177 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEdge Therapeutics has received 177 “underperform” votes. (Add your “underperform” vote.)Community SentimentEdge Therapeutics has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote “Outperform” if you believe EDGE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEdge Therapeutics does not currently pay a dividend.Dividend GrowthEdge Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edge Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.10% of the stock of Edge Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.04% of the stock of Edge Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioEdge Therapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDGE Previous Symbol CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone800-208-3343Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book2.45Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-40,860,000.00 Net MarginsN/A Return on Equity-81.29% Return on Assets-56.92%Miscellaneous EmployeesN/A Outstanding Shares31,510,000Market Cap$73.42 million Next Earnings DateN/A OptionableOptionable Receive EDGE News and Ratings via Email Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.16. View Edge Therapeutics' earnings history. Who are some of Edge Therapeutics' key competitors? Some companies that are related to Edge Therapeutics include Aldeyra Therapeutics (ALDX), Urovant Sciences (UROV), Concert Pharmaceuticals (CNCE), Cassava Sciences (SAVA), Immunic (IMUX), Osmotica Pharmaceuticals (OSMT), VYNE Therapeutics (VYNE), Selecta Biosciences (SELB), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), Affimed (AFMD), Arbutus Biopharma (ABUS), Chiasma (CHMA), Paratek Pharmaceuticals (PRTK) and Liminal BioSciences (LMNL). View all competitors. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BIOLINERX LTD/S (BLRX), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP) and Fate Therapeutics (FATE). Who are Edge Therapeutics' key executives? Edge Therapeutics' management team includes the following people: Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 54)Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 57)Mr. Andrew Saik, Chief Financial Officer (Age 50)Mr. W. Bradford Middlekauff, Sr. VP, Gen. Counsel & Sec. (Age 57)Mr. William Shatynski, Sr. Director of Financial Reporting & Controller What is Edge Therapeutics' stock symbol? Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE." What is Edge Therapeutics' stock price today? One share of EDGE stock can currently be purchased for approximately $2.33. How big of a company is Edge Therapeutics? Edge Therapeutics has a market capitalization of $73.42 million. What is Edge Therapeutics' official website? The official website for Edge Therapeutics is www.edgetherapeutics.com. How can I contact Edge Therapeutics? Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
